Circulating fibroblast growth factor-23 is associated with fat mass and dyslipidemia in two independent cohorts of elderly individuals

Majd A I Mirza, Johan Alsiö, Ann Hammarstedt, Reinhold G. Erben, Karl Michaëlsson, Åsa Tivesten, Richard Marsell, Eric Orwoll, Magnus K. Karlsson, Östen Ljunggren, Dan Mellström, Lars Lind, Claes Ohlsson, Tobias E. Larsson

Research output: Contribution to journalArticle

101 Citations (Scopus)

Abstract

Objective- Disturbances in mineral metabolism define an increased cardiovascular risk in patients with chronic kidney disease. Fibroblast growth factor-23 (FGF23) is a circulating regulator of phosphate and vitamin D metabolism and has recently been implicated as a putative pathogenic factor in cardiovascular disease. Because other members of the FGF family play a role in lipid and glucose metabolism, we hypothesized that FGF23 would associate with metabolic factors that predispose to an increased cardiovascular risk. The goal of this study was to investigate the relationship between FGF23 and metabolic cardiovascular risk factors in the community. Methods and results- Relationships between serum FGF23 and body mass index (BMI), waist circumference, waist-to-hip ratio, serum lipids, and fat mass were examined in 2 community-based, cross-sectional cohorts of elderly whites (Osteoporotic Fractures in Men Study: 964 men aged 75±3.2; Prospective Investigation of the Vasculature in Uppsala Seniors study: 946 men and women aged 70). In both cohorts, FGF23 associated negatively with high-density lipoprotein and apolipoprotein A1 (7% to 21% decrease per 1-SD increase in log FGF23; P

Original languageEnglish (US)
Pages (from-to)219-227
Number of pages9
JournalArteriosclerosis, Thrombosis, and Vascular Biology
Volume31
Issue number1
DOIs
StatePublished - Jan 2011

Fingerprint

Dyslipidemias
Fats
Osteoporotic Fractures
Waist-Hip Ratio
Apolipoprotein A-I
Waist Circumference
HDL Lipoproteins
Serum
Chronic Renal Insufficiency
Lipid Metabolism
Vitamin D
Minerals
fibroblast growth factor 23
Body Mass Index
Cardiovascular Diseases
Phosphates
Lipids
Glucose

Keywords

  • cardiovascular disease prevention
  • diabetes mellitus
  • elderly
  • epidemiology
  • FGF-23
  • FGF23
  • Fibroblast growth factor-23
  • growth factors
  • lipids
  • metabolism

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Circulating fibroblast growth factor-23 is associated with fat mass and dyslipidemia in two independent cohorts of elderly individuals. / Mirza, Majd A I; Alsiö, Johan; Hammarstedt, Ann; Erben, Reinhold G.; Michaëlsson, Karl; Tivesten, Åsa; Marsell, Richard; Orwoll, Eric; Karlsson, Magnus K.; Ljunggren, Östen; Mellström, Dan; Lind, Lars; Ohlsson, Claes; Larsson, Tobias E.

In: Arteriosclerosis, Thrombosis, and Vascular Biology, Vol. 31, No. 1, 01.2011, p. 219-227.

Research output: Contribution to journalArticle

Mirza, MAI, Alsiö, J, Hammarstedt, A, Erben, RG, Michaëlsson, K, Tivesten, Å, Marsell, R, Orwoll, E, Karlsson, MK, Ljunggren, Ö, Mellström, D, Lind, L, Ohlsson, C & Larsson, TE 2011, 'Circulating fibroblast growth factor-23 is associated with fat mass and dyslipidemia in two independent cohorts of elderly individuals', Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 31, no. 1, pp. 219-227. https://doi.org/10.1161/ATVBAHA.110.214619
Mirza, Majd A I ; Alsiö, Johan ; Hammarstedt, Ann ; Erben, Reinhold G. ; Michaëlsson, Karl ; Tivesten, Åsa ; Marsell, Richard ; Orwoll, Eric ; Karlsson, Magnus K. ; Ljunggren, Östen ; Mellström, Dan ; Lind, Lars ; Ohlsson, Claes ; Larsson, Tobias E. / Circulating fibroblast growth factor-23 is associated with fat mass and dyslipidemia in two independent cohorts of elderly individuals. In: Arteriosclerosis, Thrombosis, and Vascular Biology. 2011 ; Vol. 31, No. 1. pp. 219-227.
@article{5feb9e2403c44adc9f81d360715c8365,
title = "Circulating fibroblast growth factor-23 is associated with fat mass and dyslipidemia in two independent cohorts of elderly individuals",
abstract = "Objective- Disturbances in mineral metabolism define an increased cardiovascular risk in patients with chronic kidney disease. Fibroblast growth factor-23 (FGF23) is a circulating regulator of phosphate and vitamin D metabolism and has recently been implicated as a putative pathogenic factor in cardiovascular disease. Because other members of the FGF family play a role in lipid and glucose metabolism, we hypothesized that FGF23 would associate with metabolic factors that predispose to an increased cardiovascular risk. The goal of this study was to investigate the relationship between FGF23 and metabolic cardiovascular risk factors in the community. Methods and results- Relationships between serum FGF23 and body mass index (BMI), waist circumference, waist-to-hip ratio, serum lipids, and fat mass were examined in 2 community-based, cross-sectional cohorts of elderly whites (Osteoporotic Fractures in Men Study: 964 men aged 75±3.2; Prospective Investigation of the Vasculature in Uppsala Seniors study: 946 men and women aged 70). In both cohorts, FGF23 associated negatively with high-density lipoprotein and apolipoprotein A1 (7{\%} to 21{\%} decrease per 1-SD increase in log FGF23; P",
keywords = "cardiovascular disease prevention, diabetes mellitus, elderly, epidemiology, FGF-23, FGF23, Fibroblast growth factor-23, growth factors, lipids, metabolism",
author = "Mirza, {Majd A I} and Johan Alsi{\"o} and Ann Hammarstedt and Erben, {Reinhold G.} and Karl Micha{\"e}lsson and {\AA}sa Tivesten and Richard Marsell and Eric Orwoll and Karlsson, {Magnus K.} and {\"O}sten Ljunggren and Dan Mellstr{\"o}m and Lars Lind and Claes Ohlsson and Larsson, {Tobias E.}",
year = "2011",
month = "1",
doi = "10.1161/ATVBAHA.110.214619",
language = "English (US)",
volume = "31",
pages = "219--227",
journal = "Arteriosclerosis, Thrombosis, and Vascular Biology",
issn = "1079-5642",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

TY - JOUR

T1 - Circulating fibroblast growth factor-23 is associated with fat mass and dyslipidemia in two independent cohorts of elderly individuals

AU - Mirza, Majd A I

AU - Alsiö, Johan

AU - Hammarstedt, Ann

AU - Erben, Reinhold G.

AU - Michaëlsson, Karl

AU - Tivesten, Åsa

AU - Marsell, Richard

AU - Orwoll, Eric

AU - Karlsson, Magnus K.

AU - Ljunggren, Östen

AU - Mellström, Dan

AU - Lind, Lars

AU - Ohlsson, Claes

AU - Larsson, Tobias E.

PY - 2011/1

Y1 - 2011/1

N2 - Objective- Disturbances in mineral metabolism define an increased cardiovascular risk in patients with chronic kidney disease. Fibroblast growth factor-23 (FGF23) is a circulating regulator of phosphate and vitamin D metabolism and has recently been implicated as a putative pathogenic factor in cardiovascular disease. Because other members of the FGF family play a role in lipid and glucose metabolism, we hypothesized that FGF23 would associate with metabolic factors that predispose to an increased cardiovascular risk. The goal of this study was to investigate the relationship between FGF23 and metabolic cardiovascular risk factors in the community. Methods and results- Relationships between serum FGF23 and body mass index (BMI), waist circumference, waist-to-hip ratio, serum lipids, and fat mass were examined in 2 community-based, cross-sectional cohorts of elderly whites (Osteoporotic Fractures in Men Study: 964 men aged 75±3.2; Prospective Investigation of the Vasculature in Uppsala Seniors study: 946 men and women aged 70). In both cohorts, FGF23 associated negatively with high-density lipoprotein and apolipoprotein A1 (7% to 21% decrease per 1-SD increase in log FGF23; P

AB - Objective- Disturbances in mineral metabolism define an increased cardiovascular risk in patients with chronic kidney disease. Fibroblast growth factor-23 (FGF23) is a circulating regulator of phosphate and vitamin D metabolism and has recently been implicated as a putative pathogenic factor in cardiovascular disease. Because other members of the FGF family play a role in lipid and glucose metabolism, we hypothesized that FGF23 would associate with metabolic factors that predispose to an increased cardiovascular risk. The goal of this study was to investigate the relationship between FGF23 and metabolic cardiovascular risk factors in the community. Methods and results- Relationships between serum FGF23 and body mass index (BMI), waist circumference, waist-to-hip ratio, serum lipids, and fat mass were examined in 2 community-based, cross-sectional cohorts of elderly whites (Osteoporotic Fractures in Men Study: 964 men aged 75±3.2; Prospective Investigation of the Vasculature in Uppsala Seniors study: 946 men and women aged 70). In both cohorts, FGF23 associated negatively with high-density lipoprotein and apolipoprotein A1 (7% to 21% decrease per 1-SD increase in log FGF23; P

KW - cardiovascular disease prevention

KW - diabetes mellitus

KW - elderly

KW - epidemiology

KW - FGF-23

KW - FGF23

KW - Fibroblast growth factor-23

KW - growth factors

KW - lipids

KW - metabolism

UR - http://www.scopus.com/inward/record.url?scp=78650889020&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78650889020&partnerID=8YFLogxK

U2 - 10.1161/ATVBAHA.110.214619

DO - 10.1161/ATVBAHA.110.214619

M3 - Article

VL - 31

SP - 219

EP - 227

JO - Arteriosclerosis, Thrombosis, and Vascular Biology

JF - Arteriosclerosis, Thrombosis, and Vascular Biology

SN - 1079-5642

IS - 1

ER -